Israel’s BioBlast announced promising interim results from its Phase II study of its Cabaletta treatment for oculopharyngeal muscular dystrophy (OPMD). Due to the success BioBlast seeks to fast track a Phase III study in 2016, leading to a 2017 launch date.
http://www.globes.co.il/en/article-bioblast-orphan-drug-gives-hope-to-opmd-patients-1001076594